Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells

Molecular and Cellular Endocrinology

Volumn 302, Issue 1, 2009, Pages 41-48

  Valdehita, Ana ^a   Bajo, Ana M ^a   Schally, Andrew V ^b   Varga, Jozsef L ^b   Carmena, María J ^a   Prieto, Juan C ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Drug treatment; EGFR; GHRH analogues; HER2; VIP receptors

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OLIGONUCLEOTIDE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 60849105645     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.11.024     Document Type: Article

References (43)

1. Anido J., Matar P., Albanell J., Guzmán M., Rojo F., Arribas J., Averbuch S., and Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9 (2003) 1274-1283
2. Atalay G., Cardoso F., Awada A., and Piccart M.J. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol. 14 (2003) 1346-1363
3. Bellezza I., Bracarda S., Caserta C., and Minelli A. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. Mol. Genet. Metab. 88 (2006) 114-122
4. Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., and Parsons S.J. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20 (2001) 1465-1475
5. Bertelsen L.S., Barrett K.E., and Keely S.J. Gs protein-coupled receptor agonists induce transactivation of the epidermal growth factor receptor in T84 cells: implications for epithelial secretory responses. J. Biol. Chem. 279 (2004) 6271-6279
6. Bhola N.E., and Grandis J.R. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci. 13 (2008) 1857-1865
7. Biscardi J.S., Ishizawar R.C., Silva C.M., and Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2 (2000) 203-210
8. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
9. Christensen J.G., Schreck R.E., Chan E., Wuang X., Yang C., Liu L., Cui J., Sun L., Wei J., Cherrigton J.M., and Mendel D.B. High levels of HER2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Cancer Res. 7 (2001) 4230-4238
10. Daly R.J. Take your partners, please-signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 16 (1999) 255-263
11. Daub H., Wallasch C., Lankenau A., Herrlich A., and Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 16 (1997) 7032-7044
12. Edwards J., Traynor P., Munro A.F., Pirret C.F., Dunne B., and Bartlett J.M. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin. Cancer Res. 12 (2006) 123-130
13. Eguchi E., Numaguchi K., Iwasaki H., Matsumoto T., Yamakawa T., Utsunomiya H., Motley E.D., Kawakatsu H., Owada K.M., Hirata Y., Marumo F., and Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J. Biol. Chem. 273 (1998) 8890-8896
14. Eriksson M., Lind B., Uvnas-Morbeg K., and Hökfelt T. Distribution and origin of peptide containing nerve fibres in the rat and human mammary gland. Neuroscience 70 (1996) 227-245
15. Fischer O.M., Hart S., Gschwind A., and Ullrich A. EGFR signal transactivation in cancer cells. Biochem. Soc. Trans. 31 (2003) 1203-1208
16. Formento P., Hannoun-Levi J.M., Fischel J.L., Magné N., Etienne-Grimaldi M.C., and Milano G. Dual Her1-2 targeting of hormone-refractory prostate cancer by ZD1389 and Trastuzumab. Eur. J. Cancer 40 (2004) 2837-2844
17. Gutiérrez-Cañas I., Juarranz M.G., Collado B., Rodríguez-Henche N., Chiloeches A., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK and PI3K. Prostate 63 (2005) 44-55
18. Ito Y., Tokudome N., Sugihara T., Takahashi S., and Hatake K. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. Breast Cancer 14 (2007) 156-162
19. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
20. Konecny G.E., Wilson C.A., and Slamon D.J. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?. J. Natl. Cancer Inst. 95 (2003) 1813-1815
21. Laburthe M., and Couvineau A. Molecular pharmacology and structure of PACAP receptors for VIP and PACAP. Regul. Pept. 108 (2002) 165-173
22. Lin N.U., and Winer E.P. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 6 (2004) 204-210
23. Luttrell D.K., and Luttrell L.M. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 23 (2004) 7969-7978
24. Mass R.D. The HER receptor family: a rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 932-940
25. Moody T.W., Czerwinski G., Tarasova N.Y., and Michejda C.J. VIP-ellipticine derivates inhibit the growth of breast cancer cells. Life Sci. 71 (2002) 1005-1014
26. Moody T.W., and Gozes I. Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr. Pharm. Des. 13 (2007) 1099-1104
27. Moody T.W., Hill J.M., and Jensen R.T. VIP as a trophic factor in the CNS and cancer cells. Peptides 24 (2003) 163-177
28. Moody T.W., and Jensen R.T. Breast cancer VPAC1 receptors. Ann. N. Y. Acad. Sci. 1070 (2006) 436-439
29. Moody T.W., Leyton J., Chan D., Brenneman D.C., Fridkin M., Gelber E., Levy A., and Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res. Treat. 68 (2001) 55-64
30. Plonowski A., Varga J.L., Schally A.V., Krupa M., Groot K., and Halmos G. Inhibition of PC-3 human prostate cancers by analogs of growth-hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. Int. J. Cancer 98 (2002) 624-629
31. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., and Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402 (1999) 884-888
32. Rekasi Z., Varga J.L., Schally A.V., Halmos G., Groot K., and Czompoly T. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1218-1223
33. Richards J. New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. Mol. Endocrinol. 15 (2001) 209-218
34. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell Physiol. 213 (2007) 589-602
35. Schally A.M., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J., and Halmos G. Hypothalamic hormones and cancer. Front. Neuroendocrinol. 22 (2001) 248-291
36. Sotomayor S., Carmena M.J., Schally A.V., Varga J.L., Sánchez-Chapado M., Prieto J.C., and Bajo A.M. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. Int. J. Oncol. 31 (2007) 1223-1230
37. Stork P.J.S., and Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12 (2002) 258-266
38. Tsutsui S., Kataoka A., Ohno S., Murakami S., Kinoshita J., and Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin. Cancer Res. 8 (2002) 3454-3460
39. Valdehita A., Carmena M.J., Collado B., Prieto J.C., and Bajo A.M. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul. Pept. 144 (2007) 101-108
40. Varga J.L., Schally A.V., Csernus V.J., Zarandi M., Halmos G., Groot K., and Rekasi Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 692-697
41. Werner H., Koch Y., Fridkin M., Fahrenkrug J., and Gozes I. High levels of vasoactive intestinal peptide in human milk. Biochem. Biophys. Res. Commun. 133 (1985) 228-232
42. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. 2 (2001) 127-137
43. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C., Fridkin M., Gozes I., and Moody T.W. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56 (1996) 3486-3489